Unapproved Cancer Blood Tests Gain Popularity, Raising Expert Concerns

New blood tests that promise to detect multiple cancers early are attracting patient interest. However, these tests lack approval from key U.S. regulators, creating a divide between public demand and medical caution. Companies market these tools directly to consumers. The tests aim to find cancer signals in the blood, often before symptoms appear. Despite their appeal, the U.S. Food and Drug Administration (FDA) has not approved them. Major medical groups warn that the tests' accuracy and real-world benefits remain unproven. Doctors worry about false alarms. An incorrect positive result can lead to unnecessary, invasive follow-up procedures and significant patient anxiety. Conversely, a false negative could provide dangerous false reassurance, potentially delaying a true diagnosis. Experts emphasize that these tests are not yet replacements for standard screenings. Patients eager for early detection are driving demand. This has placed many physicians in a difficult position, balancing hope for innovation with their duty to recommend only proven care.